Two soluble glycosyltransferases glycosylate less efficiently in vivo than their membrane bound counterparts.
Many Golgi glycosyltransferases are type II membrane proteins which are cleaved to produce soluble forms that are released from cells. Cho and Cummings recently reported that a soluble form of alpha1, 3-galactosyltransferase was comparable to its membrane bound counterpart in its ability to galactosylate newly synthesized glycoproteins (Cho,S.K. and Cummings,R.D. (1997) J. Biol. Chem., 272, 13622-13628). To test the generality of their findings, we compared the activities of the full length and soluble forms of two such glycosyltransferases, ss1,4 N-Acetylgalactosaminyltransferase (GM2/GD2/ GA2 synthase; GalNAcT) and beta galactoside alpha2,6 sialyltransferase (alpha2,6-ST; ST6Gal I), for production of their glycoconjugate products in vivo . Unlike the full length form of GalNAcT which produced ganglioside GM2 in transfected cells, soluble GalNAcT did not produce detectable GM2 in vivo even though it possessed in vitro GalNAcT activity comparable to that of full length GalNAcT. When compared with cells expressing full length alpha2,6-ST, cells expressing a soluble form of alpha2,6-ST contained 3-fold higher alpha2,6-ST mRNA levels and secreted 7-fold greater alpha2,6-ST activity as measured in vitro , but in striking contrast contained 2- to 4-fold less of the alpha2,6-linked sialic acid moiety in cellular glycoproteins in vivo . In summary these results suggest that unlike alpha1,3-galactosyltransferase the soluble forms of these two glycosyltransferases are less efficient at glycosylation of membrane proteins and lipids in vivo than their membrane bound counterparts.
Zhu
G
G
Departments of Biological and Biophysical Sciences and Biochemistry and Molecular Biology, Schools of Dentistry and Medicine and James G. Brown Cancer Center, University of Louisville, Louisville, KY 40292, USA.
Allende
M L
ML
Jaskiewicz
E
E
Qian
R
R
Darling
D S
DS
Worth
C A
CA
Colley
K J
KJ
Young
W W
WW
D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D015153:Blotting, Western; D016466:CHO Cells; D006224:Cricetinae; D017931:DNA Primers; D006001:Glycoconjugates / Q000378:metabolism; D006031:Glycosylation; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D017350:N-Acetylgalactosaminyltransferases / Q000235:genetics / Q000378:metabolism*; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D012799:Sialyltransferases / Q000235:genetics / Q000378:metabolism*; D012995:Solubility; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase; D000097763:Polypeptide N-acetylgalactosaminyltransferase
D017931:DNA Primers; D006001:Glycoconjugates; D008565:Membrane Proteins; D017350:N-Acetylgalactosaminyltransferases; D019158:N-Acetylneuraminic Acid; D011993:Recombinant Fusion Proteins; D012799:Sialyltransferases; D000094802:beta-D-Galactoside alpha 2-6-Sialyltransferase; D000097763:Polypeptide N-acetylgalactosaminyltransferase